

**NOW  
APPROVED**  
An innovation  
in mCRC



**LIVE  
PROGRAM**

## Introducing the First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade<sup>1-3</sup>

**FEATURING:**

**HOSTED BY:**

**LOCATION:**

**DATE:**

**TIME:**

**REGISTER HERE:**

**RSVP BY:**

**Meeting Code:**

### **INDICATION**

FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

### **IMPORTANT SAFETY INFORMATION**

#### **WARNINGS AND PRECAUTIONS**

- **Hypertension** occurred in 49% of 911 patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity of hypertension.

**Please see additional Important Safety Information on the next page and visit <https://takeda.info/Fruzaqla-Prescribing-Information> for full Prescribing Information.**

**Attendance is limited to Licensed and Medically Oriented US Healthcare Professionals for whom the content is approved.**

Takeda acts in accordance with the PhRMA Code on Interactions with Healthcare Professionals. The PhRMA Code states that inclusion of a Healthcare Professional's spouse or guest at an education program is not appropriate. Your support of these ethical guidelines will help to ensure a high-quality learning environment for all participating Healthcare Professionals.

The personal information you provide may be shared with Takeda, its affiliates, and companies working with Takeda for the purpose of completing your registration for this program and as required by law. Takeda or companies working with Takeda may also send you information on disease state awareness material, Takeda products and services, and other health-related topics using the contact information you provide.

Sponsored by Takeda Oncology. Please note that this is not a continuing medical education (CME) program.

## IMPORTANT SAFETY INFORMATION (continued)

### WARNINGS AND PRECAUTIONS (continued)

- **Hemorrhagic Events** including serious, fatal events can occur with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced gastrointestinal hemorrhage, including 1% with a Grade  $\geq 3$  event and 2 patients with fatal hemorrhages. Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants.
- **Infections.** FRUZAQLA can increase the risk of infections, including fatal infections. In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%). Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.
- **Gastrointestinal Perforation** occurred in patients treated with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 1.3% experienced a Grade  $\geq 3$  gastrointestinal perforation, including one fatal event. Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.
- **Hepatotoxicity.** FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade  $\geq 3$  events in 5%, and fatal events in 0.2% of patients. Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests.
- **Proteinuria.** FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade  $\geq 3$  events. Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria  $\geq 2$  g/24 hours, withhold FRUZAQLA until improvement to  $\leq$  Grade 1 proteinuria and resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome.
- **Palmar-Plantar Erythrodysesthesia (PPE)** occurred in 35% of 911 patients treated with FRUZAQLA, including 8% with Grade 3 events. Based on severity of PPE, withhold FRUZAQLA and then resume at the same or reduced dose.
- **Posterior Reversible Encephalopathy Syndrome (PRES)**, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 911 patients treated with FRUZAQLA. Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.
- **Impaired Wound Healing.** In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence. Do not administer FRUZAQLA for at least 2 weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.
- **Arterial Thromboembolic Events.** In 911 patients with mCRC treated with FRUZAQLA, 0.8% of patients experienced an arterial thromboembolic event. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism, discontinue FRUZAQLA.
- **Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF).** FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.
- **Embryo-Fetal Toxicity.** Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of childbearing potential and males with female partners of childbearing potential to use effective contraception during treatment with FRUZAQLA and for 2 weeks after the last dose.

### ADVERSE REACTIONS

The most common adverse reactions (incidence  $\geq 20\%$ ) following treatment with FRUZAQLA included hypertension, palmar-plantar erythrodysesthesia (hand-foot skin reactions), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.

**DRUG INTERACTIONS:** Avoid concomitant administration of FRUZAQLA with strong or moderate CYP3A inducers.

### USE IN SPECIFIC POPULATIONS

- **Lactation:** Advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see Important Safety Information on this page and visit**

**<https://takeda.info/Fruzaqla-Prescribing-Information> for full Prescribing Information.**

**Please visit <https://takeda.info/CO-fruzaqla-price-form> (CO residents),**

**<https://takeda.info/VT-Fruzaqla-short-price-disclosure> (VT residents),**

**or <https://takeda.info/CT-fruzaqla-price-form> (CT residents)**

**to view FRUZAQLA Product Pricing Information.**

**References:** 1. FRUZAQLA (fruquintinib) prescribing information. Takeda Pharmaceuticals.

2. Conroy R. FDA gives priority review to fruquintinib in metastatic colorectal cancer.

Cancer Network. Published May 26, 2023. Accessed September 19, 2023. <https://www.cancernetwork.com/view/fda-gives-priority-review-to-fruquintinib-in-metastatic-colorectal-cancer>

3. Zhang Y, et al. *Cancer Manag Res.* 2019;11:7787-7803.

TAKEDA® and the TAKEDA logo® are registered trademarks of Takeda Pharmaceutical Company Limited.

FRUZAQLA and  are trademarks of HUTCHMED Group Enterprises Limited, used under license.

©2023 Takeda Pharmaceuticals U.S.A., Inc.  
All rights reserved. 11/2023 USO-FRQ-0096



ONCOLOGY

  
**Fruzaqla™**  
**(fruquintinib) capsules**  
**5 mg • 1 mg**